Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone

Journal of Clinical Oncology

Volumn 24, Issue 18, 2006, Pages 2828-2835

  Berry, Donna L ^a   Moinpour, Carol M ^a   Jiang, Caroline S ^a   Ankerst, Donna Pauler ^a   Petrylak, Daniel P ^a   Vinson, Lynne V ^a   Lara, Primo N ^a   Jones, Sharon ^a   Taplin, Mary E ^a   Burch, Patrick A ^a   Hussain, Maha H A ^a   Crawford, E David ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGED; ANALGESIA; ARTICLE; BONE PAIN; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BONE TUMOR; METASTASIS; MIDDLE AGED; PAIN; PAIN ASSESSMENT; PALLIATIVE THERAPY; PATHOLOGY; PROSTATE TUMOR; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PREDNISONE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TAXOIDS;

EID: 33745570865     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.8207     Document Type: Article

References (27)

1. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989
2. Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042, 1998
3. Petrylak D, Tangen C, Hussian M, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
4. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
5. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al: Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94:1457-1465, 2002
6. Petrylak DP: Future directions in the treatment of androgen-independent prostate cancer. Urology 65:8-12, 2005
7. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
8. Fayers P, Aaronson N, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual (3rd Ed). Brussels, Belgium, EORTC, 2001
9. Melzack R: The short-form McGill Pain Questionnaire. Pain 30:191-197, 1987
10. Melzack R: The McGill pain questionnaire: From description to measurement. Anesthesiology 103:199-202, 2005
11. Wilkie DJ, Lovejoy N, Dodd M, et al: Cancer pain intensity measurement: Concurrent validity of three instruments-finger dynamometer, pain intensity number scale, visual analogue scale. The Hospice Journal 6:1-13, 1990
12. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
13. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989
14. Osoba D, Tannock IF, Ernst DS, et al: Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17:1654-1663, 1999
15. Geyer CE Jr, Green SJ, Moinpour CM, et al: Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study. Breast Cancer Res Treat 51:169-181, 1998
16. Little RJ, Wang Y: Pattern-mixture models for multivariate incomplete data with covariates. Biometrics 52:98-111, 1996
17. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
18. Zoorob RJ, Cender D: A different look at corticosteroids. Am Fam Physician 58:443-450, 1998
19. Oudard S, Banu E, Beuzeboc P, et al: Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23:3343-3351, 2005
20. Berry DL, Wilkie DJ, Huang HY, et al: Cancer pain and common pain: A comparison of patient-reported intensities. Oncol Nurs Forum 26:721-726, 1999
21. Beer TM, Eilers KM, Garzotto M, et al: Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer 100:758-763, 2004
22. Bernhard J, Cella DF, Coates AS, et al: Missing quality of life data in cancer clinical trials: Serious problems and challenges. Stat Med 17:517-532, 1998
23. Pauler DK, McCoy S, Moinpour C: Pattern mixture models for longitudinal quality of life studies in advanced stage disease. Stat Med 22:795-809, 2003
24. Fairclough DL: Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL, Chapman & Hall, 2002
25. Fishman M, Jacobsen P, Chen N, et al: Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23:755S, 2005 (suppl; abstr 8106)
26. Esper P, Mo F, Chodak G, et al: Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50:920-928, 1997
27. The EuroQol Group: EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 16: 199-208, 1990